China Neurovascular Devices Market to Grow with a CAGR of 7.35% through 2030

Rising Stroke Prevalence and Aging Population and Urbanization and Improved Diagnostic Penetration are expected to drive the China Neurovascular Devices Market growth in the forecast period, 2026-2030

According to TechSci Research report, “China Neurovascular Devices Market – By Region, Competition, Forecast & Opportunities, 2030F”, the China Neurovascular Devices Market stood at USD 255.56 Million in 2024 and is anticipated to grow with a CAGR of 7.35% in the forecast period, 2026-2030.

The Chinese government is strategically accelerating the development of stroke centers and neurointerventional departments within secondary and tertiary hospitals nationwide. Through targeted initiatives such as the Stroke Prevention and Control Project, a growing number of institutions are being outfitted with critical neurovascular infrastructure including digital subtraction angiography (DSA) systems and high-precision surgical platforms. This infrastructure upgrade is directly translating into higher procedural volumes, increased throughput for neurointerventions, and rising utilization of advanced neurovascular devices across public hospitals.

China is experiencing a pronounced shift in clinical practice away from traditional open neurosurgical approaches toward minimally invasive neurovascular procedures, including mechanical thrombectomy, endovascular coiling, and stent-assisted embolization. These techniques offer clear advantages in procedural accuracy, reduced complication rates, and shorter recovery times particularly critical for stroke patients. Growing clinician proficiency, supported by ongoing technical training, combined with rising patient awareness, is driving widespread adoption of these therapies not only in top-tier hospitals but also in emerging urban and semi-urban medical centers.

China’s healthcare reform efforts are reshaping the reimbursement landscape and strengthening the commercial viability of neurovascular procedures. Key reforms include the inclusion of neurointerventions under national insurance coverage and support for hospital modernization and innovation-driven procurement models. These changes are reducing financial barriers for patients and expanding the effective demand base for neurovascular devices, particularly in regions previously underserved by interventional stroke care.

A wave of technological innovation and localization is reshaping the competitive dynamics of the market. Advances in device engineering such as next-generation flow diverters, retrievable stent systems, and microcatheter-based embolization tools are improving clinical outcomes and enabling more complex interventions. Simultaneously, government-supported domestic manufacturers are delivering competitively priced, high-quality solutions through accelerated regulatory pathways and R&D incentives. This trend is rapidly improving device availability in Tier II and Tier III cities, where affordability and local technical support are critical.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "China Neurovascular Devices Market”

The China Neurovascular Devices Market is segmented into device, therapeutic application, end users, regional distribution, and company.

Based on its end user, the Hospitals segment has emerged as the predominant market leader, China’s healthcare system is hierarchically structured, and Class III hospitals especially tertiary public institutions in urban centers serve as the primary hubs for advanced neurovascular procedures. These hospitals are typically the first to receive: Digital Subtraction Angiography (DSA) systems, Hybrid operating suites, Skilled neurointerventionists trained in mechanical thrombectomy, aneurysm coiling, and flow diversion procedures. They also act as regional stroke referral centers, responsible for handling the most severe and urgent cases. Consequently, they account for a disproportionate share of high-value device consumption, including stent retrievers, aspiration catheters, and embolization coils.

National initiatives such as the Stroke Prevention and Control Project and the tiered stroke care network are heavily hospital-centric. These programs prioritize investment in: Hospital-based stroke centers, Emergency "green channel" systems for stroke patients, In-hospital clinician training programs for neurointerventional techniques. As a result, the hospitals segment continues to benefit from policy-driven funding, equipment upgrades, and clinical capacity-building, which further reinforces its lead position in the neurovascular market.

While specialty clinics are gaining traction in China’s broader healthcare landscape particularly in areas like orthopedics and cardiology their presence in neurovascular care remains limited. The nature of neurovascular procedures, which often require immediate intervention, advanced imaging, intensive care capabilities, and highly specialized staff, places them beyond the operational scope of most outpatient or standalone specialty clinics. Clinics primarily serve in a referral or follow-up capacity, rather than as primary intervention centers. Device consumption from clinics is relatively low and restricted to post-operative care or diagnostics, rather than interventional procedures.

Major companies operating in China Neurovascular Devices Market are:

• Zylox-Tonbridge
• MicroPort Scientific Corporation
• Medtronic
• Terumo (China) Holdings Co., Ltd.
• Integra LifeSciences Holdings Corporation
• Genesis MedTech
• ACANDIS GmbH
• Stryker

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The China Neurovascular Devices Market is positioned for sustained, high-impact growth, driven by a rising stroke burden, demographic aging, infrastructure modernization, and strong government policy support. As the country transitions toward more advanced, minimally invasive neurointerventions, demand for clinically effective and economically scalable device solutions will continue to accelerate. Market participants that align with China’s localized innovation agenda, strengthen hospital-based partnerships, and adapt to regional deployment dynamics will be best positioned to capture long-term value in this evolving and strategically critical healthcare segment.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“China Neurovascular Devices Market, By Device (Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Neurothrombectomy Devices, Support Devices, Trans Radial Access Devices), By Therapeutic Application (Stroke, Cerebral Artery, Cerebral Aneurysm, Others), By End User (Hospitals, Specialty Clinics, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of China Neurovascular Devices Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in China Neurovascular Devices Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]